Docetaxel with prednisone or prednisolone for the treatment of ...

More documents

Recommendations

Info

92 References 180. Kozloff M, Robin EL, Raminski D, Rao Uppuluri VS, Sylora J, Starr A, et al. A phase II study using mitoxantrone and ketoconazole in hormone resistant metastatic adenocarcinoma of the prostate [conference abstract: no. 2364]. In 2001 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD &vmview=abst_detail_view&confID=10&index= y&abstractID=2364. Accessed 11 May 2005. 181. Kuebler H, van Randenborgh H, Paul R, Breul J, Hartung R. Docetaxel-monotherapy given every 21 days in patients with metastatic hormone refractory prostate cancer (m-HRPC) – response and toxicity. Eur Urol Suppl 2003;2:25. 182. Laber DA, la Rocca RV, Glisson S, Hargis J, Schonard C. Phase II study of higher dose docetaxel in clinically deteriorating patients with hormone refractory prostate cancer (HRPC) [conference abstract: no. 2449]. In 2002 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. URL: http://www.asco.org/ portal/site/ASCO/menuitem.34d60f5624ba07fd506 fe310ee37a01d/?vgnextoid=76f8201eb61a7010Vg nVCM100000ed730ad1RCRD&vmview=abst_deta il_view&confID=16&index=y&abstractID=2449. Accessed 4 May 2005. 183. Laber DA, La Rocca RV, Glisson SD, Hargis J, Schonard C. Higher dose docetaxel in patients with hormone refractory prostate cancer (HRPC). Long-term results of a phase II study [conference abstract]. Proc Am Soc Clin Oncol 2003;22:413 (abstract 1661). URL: http://www.asco.org/portal/ site/ASCO/menuitem.34d60f5624ba07fd506fe310e e37a01d/?vgnextoid=76f8201eb61a7010VgnVCM 100000ed730ad1RCRD&vmview=abst_detail_view &confID=23&index=y&abstractID=100154 184. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium screening and phase II trial. Cancer 2004;100:2125–31. 185. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer [pdf on the Internet]. Alexandria, VA: American Society of Clinical Oncology; 2004. URL: http://www.asco.org/asco/downloads/JCO.2004.04.5 79v1.pdf. Accessed 11 May 2005. 186. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology 2002;16 (6 Suppl):63–72. 187. Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma – results of a meta-analysis. Cancer 2004;101:2755–59. 188. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171–87. 189. Mattioli R, Imperatori L, Casadei V. Preliminary experience: chemotherapy with mitoxantrone and vinblastina in elderly with advanced hormonally resistant prostate cancer. Ann Oncol 1998;9:77. 190. MedlinePlus. Corticosteroids:glucocorticoid effects (systemic) [web page on the Internet]. Bethesda, MD: US National Library of Medicine; 2005. URL: http://www.nlm.nih.gov/ medlineplus/druginfo/uspdi/202018.html. Accessed 17 June 2005. 191. Miller K, Raabe N, Trachtenberg J, Trump D, Wilding G, Das-Gupta A. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with mitoxantrone and prednisone in patients with hormone refractory prostate cancer (HRPC). Ann Oncol 2002;13 Suppl 5:91. 192. Miller K, Steiner U, Machtens S, Backhaus B, Siegsmund M, Johannsen M, et al. Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with hormone-refractory prostate cancer (HRPC): a multicenter phase II study [conference abstract]. Proc Am Soc Clin Oncol 2003;22:413 (abstr 1660). URL: http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/? vgnextoid=76f8201eb61a7010VgnVCM100000ed7 30ad1RCRD&vmview=abst_detail_view&confID= 23&index=y&abstractID=103648. Accessed 4 May 2005. 193. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229–39. 194. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689–94. 195. Nabhan C, Petrylak DP, Hussain M, Crawford ED. Chemotherapy for advanced prostate cancer [letter and reply]. N Engl J Med 2005;352:200–1. 196. National Cancer Institute. Phase II study of docetaxel in patients with hormone refractory metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 1999. URL:
http://www.cancer.gov/search/ViewClinicalTrials.asp x?cdrid=66913&version=HealthProfessional&prot ocolsearchid=1609754. Accessed 13 May 2005. 197. National Cancer Institute. Phase II randomized study of docetaxel with or without thalidomide in patients with androgen-independent metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2000. URL: http://www.cancer.gov/ search/ViewClinicalTrials.aspx?cdrid=67602& version=HealthProfessional&protocolsearchid= 1609754. Accessed 13 May 2005. 198. National Cancer Institute. Phase II randomized study of SGN-15 (cBr96-doxorubicin immunoconjugate) combined with docetaxel vs docetaxel alone in patients with hormone-refractory prostate carcinoma [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=69077&version= HealthProfessional&protocolsearchid=1609754. Accessed 13 May 2005. 199. National Cancer Institute. Phase II study of docetaxel (Taxotere) in patients with hormone-refractory prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http://www.cancer.gov/search/ViewClinicalTrials. aspx?cdrid=63293&version=HealthProfessional& protocolsearchid=1609754. Accessed 13 May 2005. 200. National Cancer Institute. Phase II study of docetaxel (Taxotere) in patients with hormone-refractory metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2002. URL: http://www.cancer.gov/search/ViewClinicalTrials. aspx?cdrid=64445&version=HealthProfessional& protocolsearchid=1609754. Accessed 13 May 2005. 201. National Cancer Institute. Phase II crossover extension study of docetaxel and imatinib mesylate in patients with androgen-independent prostate cancer and bone metastases that progressed on the docetaxel and placebo arm of MDA-ID-030008 [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.nci.nih.gov/clinical_trials/ view_clinicaltrials.aspx?cdrid=365625&version= healthprofessional. Accessed 12 May 2005. 202. National Cancer Institute. Phase II randomized study of docetaxel with versus without imatinib mesylate in patients with androgen-independent prostate cancer and bone metastases [web page on the Inernet]. Bethesda, Maryland: National Cancer Institute; 2004. [cited 2005 12 May]. URL: http://www.nci.nih.gov/ clinical_trials/view_clinicaltrials.aspx?cdrid= 354505&version=healthprofessional. Accessed 12 May 2005. 203. National Cancer Institute. Phase II study of GTI- 2040, docetaxel, and prednisone in patients with hormone-refractory prostate cancer [web page on the Inernet]. Bethesda, MD: National Cancer Institute; © Queen’s Printer and Controller of HMSO 2007. All rights reserved. Health Technology Assessment 2007; Vol. 11: No. 2 2004. URL: http://www.nci.nih.gov/clinical_trials/ view_clinicaltrials.aspx?cdrid=372951&version= healthprofessional. Accessed 12 May 2005. 204. National Cancer Institute. Phase II randomized study of docetaxel with or without oblimersen in patients with hormone-refractory adenocarcinoma of the prostate [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.cancer.gov/ search/ViewClinicalTrials.aspx?cdrid=367489& version=HealthProfessional&protocolsearchid= 1608204. Accessed 13 May 2005. 205. National Cancer Institute. Docetaxel in treating patients with stage IV prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ ct/show/NCT00003781. Accessed 16 May 2005. 206. National Cancer Institute. Docetaxel in treating patients with stage II or stage III prostate cancer [web page on the Internet]. Bethesda, Maryland: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ct/show/NCT00005096. Accessed 16 May 2005. 207. National Cancer Institute. Combination chemotherapy in treating patients with prostate cancer that has not responded to hormone therapy [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ ct/show/NCT00005960. Accessed 16 May 2005. 208. National Cancer Institute. Combination chemotherapy plus bevacizumab in treating patients with metastatic prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ct/show/NCT00016107. Accessed 16 May 2005. 209. National Cancer Institute. Combination chemotherapy plus warfarin in treating patients with prostate cancer [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ ct/show/NCT00014352. Accessed 16 May 2005. 210. National Cancer Institute. Chemotherapy with or without biological therapy in treating patients with metastatic prostate cancer that has not responded to hormone therapy [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2004. URL: http://www.clinicaltrials.gov/ct/show/NCT00005847. Accessed 16 May 2005. 211. National Cancer Institute. Phase III randomized study of hormonal therapy and docetaxel versus hormonal therapy alone in patients with metastatic prostate adenocarcinoma [web page on the Internet]. Bethesda, MD: National Cancer Institute; 2005. URL: http://www.nci.nih.gov/search/ ViewClinicalTrials.aspx?cdrid=416096&version= HealthProfessional&protocolsearchid=2124369. Accessed 12 May 2005. 212. National Cancer Institute. Docetaxel, radiation therapy, and hormone therapy in treating patients with 93
Page 1 and 2:
A systematic review and economic mo
Page 3 and 4:
A systematic review and economic mo
Page 5 and 6:
Objectives: A systematic review was
Page 7 and 8:
Glossary and list of abbreviations
Page 9 and 10:
Glossary Absolute risk reduction Th
Page 11 and 12:
Glossary continued Expected value o
Page 13 and 14:
Glossary continued Progression-free
Page 15:
List of abbreviations ASCO American
Page 18 and 19:
xvi Executive summary of study desi
Page 20 and 21:
xviii Executive summary prednisone/
Page 23 and 24:
Description of underlying health pr
Page 25 and 26:
● Patients with severe fluid rete
Page 27 and 28:
Search strategy As stated in Chapte
Page 29 and 30:
consensus and, if necessary, a thir
Page 31 and 32:
Quantity of research available A to
Page 33 and 34:
TABLE 1 Summary of included RCTs St
Page 35 and 36:
TABLE 2 Treatment comparisons relat
Page 37 and 38:
tumour response was reported for on
Page 39 and 40:
TABLE 4 Summary results table for d
Page 41 and 42:
decrease in PSA level (51 and 39% c
Page 43 and 44:
Survival (%) 100 80 60 40 20 0 0 co
Page 45 and 46:
TABLE 8 Summary results table for d
Page 47 and 48:
TABLE 9 Grade 3 or 4 adverse events
Page 49 and 50:
Also used was the core questionnair
Page 51 and 52:
these, 69 patients had measurable t
Page 53 and 54:
Effectiveness of mitoxantrone plus
Page 55 and 56:
over to receive additional mitoxant
Page 57 and 58:
Progression-free survival It is not
Page 59 and 60:
compared with corticosteroids. The
Page 61 and 62: statistically significant improveme
Page 63 and 64: Summary of studies included in the
Page 65 and 66: TABLE 19 Percentage of costs by res
Page 67 and 68: TABLE 21 Summary of submission by S
Page 69 and 70: TABLE 24 Other in-trial costs a bod
Page 71 and 72: TABLE 27 Cost-effectiveness results
Page 73 and 74: Introduction The review of cost-eff
Page 75 and 76: TABLE 28 Regression coefficients fr
Page 77 and 78: cancer QoL estimation. Studies whic
Page 79 and 80: Localised Metastatic mHRPC Bennet (
Page 81 and 82: TABLE 34 Unit costs of drugs from t
Page 83 and 84: were assigned to the total follow-u
Page 85 and 86: Probability cost-effective given da
Page 87 and 88: Probability cost-effective given da
Page 89 and 90: TABLE 43 Utility values including/e
Page 91 and 92: was set to be 1.5 years based on th
Page 93: Population value of implementation/
Page 96 and 97: 76 Discussion (CCI-NOV22) and least
Page 98 and 99: 78 Discussion subsequent chemothera
Page 101: Rodolphe Perard received funding fr
Page 104 and 105: 84 References Compendium; 2004. URL
Page 106 and 107: 86 References (D) in patients (pts)
Page 108 and 109: 88 References 100. Aventis Pharma.
Page 110 and 111: 90 References low-dose prednisone i
Page 114 and 115: 94 References locally advanced pros
Page 116 and 117: 96 References 251. Scholz MC, Guess
Page 119 and 120: Clinical effectiveness Searching fo
Page 121 and 122: 1. Prostatic Intraepithelial Neopla
Page 123 and 124: 19. donataxel 20. doxetal 21. doxmi
Page 125 and 126: 6. Mitozantrone.ti,ab. 7. Mitoxantr
Page 127 and 128: Texot or Trazoteva or Trixotene or
Page 129 and 130: 1. (docetaxel OR asodecel OR doxeta
Page 131 and 132: 10. (index of wellbeing or quality
Page 133 and 134: Appendix 2 Excluded studies Study d
Page 135 and 136: Study details Reason for exclusion
Page 137 and 138: Meeting: 2004 ASCO Annual Meeting C
Page 139 and 140: Studies of clinical effectiveness w
Page 141 and 142: Using the method outlined by Parmar
Page 143 and 144: Appendix 6 Data extraction tables
Page 145 and 146: Study details and Participant detai
Page 163 and 164:
Study details and Participant detai
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175:
Page 178 and 179:
158 Appendix 7 Ernst et al. 33 Qual
Page 181 and 182:
Appendix 9 © Queen’s Printer and
Page 183 and 184:
Sanofi-Aventis 61 Bloomfield et al.
Page 185:
Sanofi-Aventis 61 Bloomfield et al.
Page 188 and 189:
168 Appendix 10 TABLE 51 Mean (SD)
Page 190 and 191:
170 Appendix 10 TABLE 54 Distributi
Page 192 and 193:
172 Appendix 10 TABLE 57 Mean stand
Page 194 and 195:
174 Appendix 11 TABLE 63 Drug and a
Page 196 and 197:
176 Appendix 12 Scenario: moderate
Page 198 and 199:
178 Appendix 13 ● You occasionall
Page 202 and 203:
Members Chair, Professor Tom Walley
Page 204 and 205:
Members Chair, Professor Bruce Camp
Page 207:
Feedback The HTA Programme and the
show all

Docetaxel with prednisone or prednisolone for the treatment of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?